Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immunotherapy drug may delay cancer return in head and neck patients

NCT ID NCT02769520

First seen Jan 29, 2026 · Last updated May 23, 2026 · Updated 14 times

Summary

This study tests whether the immunotherapy drug pembrolizumab, given after salvage surgery, can help keep head and neck cancer from coming back in people whose cancer has already returned. About 27 adults with squamous cell carcinoma of the head and neck will receive the drug and be monitored for side effects and how long they stay cancer-free. The goal is to see if this approach improves disease-free survival compared to surgery alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • UCSD Moores Cancer Center

    La Jolla, California, 92093, United States

  • University of California Los Angeles

    Torrance, California, 90505, United States

  • University of California San Francisco

    San Francisco, California, 94115, United States

Conditions

Explore the condition pages connected to this study.